Can-Fite BioPharma Files 6-K, Incorporates Press Release
Ticker: CANF · Form: 6-K · Filed: Jul 11, 2024 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Jul 11, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, sec-form-6k, registration-statement
TL;DR
Can-Fite BioPharma filed a 6-K to update SEC filings with a press release. No new info, just procedural.
AI Summary
Can-Fite BioPharma Ltd. filed a Form 6-K on July 11, 2024, to incorporate by reference a press release into its existing Registration Statements on Form S-8 and Form F-3. This filing does not contain new financial information but serves to update ongoing SEC filings.
Why It Matters
This filing is procedural, incorporating a press release into existing SEC filings, which may contain updates relevant to investors holding securities under those registration statements.
Risk Assessment
Risk Level: low — This is a routine procedural filing that incorporates a press release into existing SEC registration statements, rather than announcing new material events or financial results.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Registrant
- July 11, 2024 (date) — Filing Date
- Form S-8 (document) — Incorporated Registration Statement
- Form F-3 (document) — Incorporated Registration Statement
FAQ
What is the purpose of this Form 6-K filing by Can-Fite BioPharma Ltd.?
The purpose of this Form 6-K is to incorporate by reference a press release (Exhibit 99.1) into the registrant's existing Registration Statements on Form S-8 and Form F-3.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on July 11, 2024.
Which SEC registration statements are being updated by this filing?
The filing incorporates information into Can-Fite BioPharma's Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384, and 333-278525) and Form F-3 (File Nos. 333-195124, 333-236064, 333-249063, 333-262055, and 333-276000).
Does this filing contain new financial information for Can-Fite BioPharma?
No, this filing is procedural and incorporates a press release into existing filings; it does not appear to contain new financial results or disclosures beyond what is in the referenced press release.
What type of issuer is Can-Fite BioPharma Ltd. according to this filing?
Can-Fite BioPharma Ltd. is identified as a Foreign Private Issuer.
Filing Stats: 274 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-07-11 07:05:26
Filing Documents
- ea0209272-6k_canfite.htm (6-K) — 10KB
- ea020927201ex99-1_canfite.htm (EX-99.1) — 13KB
- 0001213900-24-060625.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: July 11, 2024 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 2